Studies have shown that gemcitabine treatment enriches for CD133+ and CD24+ pancreatic cancer stem cells (PaCSCs), which display enhanced sphere-forming ability, drug efflux capacity, and tumorigenicity (8–10). The gene discussed is PROM1; the disease is familial pancreatic carcinoma.